The Food and Drug Administration (FDA) posted an urgent message on its website on February 21, 2019: “The FDA has concluded there is an increased risk of death with Uloric (febuxostat) compared to another gout medicine, allopurinol. This conclusion is based on our in-depth review of results from a safety clinical trial that found an increased risk … [Read more...]
Drug Used to Treat Gout Is Dangerous, FDA Warns
On February 21, 2019, the Food and Drug Administration (FDA) posted the following urgent message on its website: “The FDA has concluded there is an increased risk of death with Uloric (febuxostat) compared to another gout medicine, allopurinol. This conclusion is based on our in-depth review of results from a safety clinical trial that found an … [Read more...]
Astrazeneca Initiates Voluntary Nationwide Recall of One Lot of Brilinta 90 mg Professional Sample Bottles Due to Report of Another Medicine in One Bottle From That Lot
Voluntary recall limited to Lot # JB5047 of BRILINTA® (ticagrelor) 90 mg tablets, 8-count Professional (Physician) Sample Bottles Other forms or dosage strengths of BRILINTA, including medicine obtained via US retail or mail order pharmacies, are not affected by this voluntary recall AstraZeneca today announced that the Company is notifying … [Read more...]
Recent Comments